Article summary
This week's edition of Life Sciences weekly highlights includes analysis of inventive step being limited to the claims specified within a patent in Teva v Novartis and review of the EU CE marking and US FDA approval process considerations for medical devices software, as well as, news of a first medtech strategy for the NHS, the British pharmaceutical industry calling for the DHSC to not raise the statutory scheme’s revenue clawback rate from pharma revenues for medicines sold to the NHS, the EMA publishing a report on paediatric clinical trials that highlights key achievements made four years into its ten-year action plan with guidance for the stepwise Paediatric Investigation Plan (PIP) pilot and MedTech Europe has published its feedback on the EU Cyber Resilience Act (CRA), among other stories.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial